Paper43164
A double-blind crossover comparison of pindolol, metoprolol, atenolol and labetalol in mild to moderate hypertension.
McNeil JJ and 1 other. Br J Clin Pharmacol, 1979. Cited by 33 papers, by iCite.
11 sourcespapers-2026-11-12-0.1.0
Cite this record
ConductScience Library. A double-blind crossover comparison of pindolol, metoprolol, atenolol and labetalol in mild to moderate hypertension. Papers, record 43164. Release papers-2026-11-12-0.1.0, 12 Nov 2026. https://conductscience.org/library/papers/43164
Paper
PubMed's record of the paper, with iCite's citation figures. No abstract is shown.
Topics16
NLM's MeSH indexing of the paper, its major topics first.
| MeSH term | Major |
|---|---|
| Adrenergic beta-Antagonists | Major topic |
| Ethanolamines | Major topic |
| Hypertension | Major topic |
| Labetalol | Major topic |
| Adult | |
| Aged | |
| Atenolol | |
| Clinical Trials as Topic | |
| Double-Blind Method | |
| Female | |
| Humans | |
| Male | |
| Metoprolol | |
| Middle Aged | |
| Pindolol | |
| Time Factors |
Source PubMed
References6
The papers the reference list in PubMed's record names, those in our copy of PubMed, in the list's order.
| Order | PMID | Title | Journal | Year | In Papers | Source |
|---|---|---|---|---|---|---|
| 1 | 14,172,036 | USE OF PROPRANOLOL (INDERAL) IN TREATMENT OF HYPERTENSION. | Br Med J | 1964 | https://conductscience.org/library/papers/14172036 | PubMed |
| 2 | 14,501 | Experience with pindolol, a betareceptor blocker, in the treatment of hypertension. | Am J Med | 1976 | https://conductscience.org/library/papers/14501 | PubMed |
| 3 | 7,342 | Comparison of antihypertensive activity of beta-blocking drugs during chronic treatment. | Br Med J | 1976 | https://conductscience.org/library/papers/7342 | PubMed |
| 4 | 4,404,279 | The use of prindolol (Visken) in the treatment of hypertension. | Med J Aust | 1972 | https://conductscience.org/library/papers/4404279 | PubMed |
| 5 | 5,572,519 | Effect of bronchodilator drugs on arterial blood gas tensions in bronchial asthma. | Postgrad Med J | 1971 | https://conductscience.org/library/papers/5572519 | PubMed |
| 6 | 22,026 | How safe are beta-blocking drugs? | Med J Aust | 1977 | https://conductscience.org/library/papers/22026 | PubMed |
Cited by16
The papers in our copy of PubMed whose reference list names this one, newest first. iCite, which reads more sources, counts 33 citations.
| PMID | Title | Journal | Year | In Papers | Source |
|---|---|---|---|---|---|
| 7,093,094 | Alternatives to beta-blockade in therapy of hypertension with angina pectoris: role of nifedipine or of labetalol. | Br J Clin Pharmacol | 1982 | https://conductscience.org/library/papers/7093094 | PubMed |
| 7,075,640 | Comparison of labetalol and clonidine in hypertension. | Eur J Clin Pharmacol | 1982 | https://conductscience.org/library/papers/7075640 | PubMed |
| 6,370,541 | Clinical pharmacokinetics of labetalol. | Clin Pharmacokinet | 1984 | https://conductscience.org/library/papers/6370541 | PubMed |
| 6,151,891 | Combined alpha- and beta-receptor inhibition in the treatment of hypertension. | Drugs | 1984 | https://conductscience.org/library/papers/6151891 | PubMed |
| 6,151,889 | Pharmacology of combined alpha-beta-blockade. I. | Drugs | 1984 | https://conductscience.org/library/papers/6151889 | PubMed |
| 6,133,735 | Beta-adrenoceptor blocking drugs and partial agonist activity. Is it clinically relevant? | Drugs | 1983 | https://conductscience.org/library/papers/6133735 | PubMed |
| 6,125,183 | Beta-adrenoceptor blocking drugs: the relevance of intrinsic sympathomimetic activity. | Br J Clin Pharmacol | 1982 | https://conductscience.org/library/papers/6125183 | PubMed |
| 6,125,181 | The influence of beta-adrenoceptor blockade on left ventricular function. | Br J Clin Pharmacol | 1982 | https://conductscience.org/library/papers/6125181 | PubMed |
| 6,125,172 | The effect of intrinsic sympathomimetic activity of beta-adrenoceptor blockers on circadian heart rate. | Br J Clin Pharmacol | 1982 | https://conductscience.org/library/papers/6125172 | PubMed |
| 6,124,265 | Comparison of labetalol with other anti-hypertensive drugs. | Br J Clin Pharmacol | 1982 | https://conductscience.org/library/papers/6124265 | PubMed |
| 4,054,195 | Atenolol versus pindolol: side-effects in hypertension. | Eur J Clin Pharmacol | 1985 | https://conductscience.org/library/papers/4054195 | PubMed |
| 3,107,605 | Effects of felodipine on haemodynamics and exercise capacity in patients with angina pectoris. | Br J Clin Pharmacol | 1987 | https://conductscience.org/library/papers/3107605 | PubMed |
| 2,908,732 | Properties of labetalol, a combined alpha- and beta-blocking agent, relevant to the treatment of myocardial ischemia. | Cardiovasc Drugs Ther | 1988 | https://conductscience.org/library/papers/2908732 | PubMed |
| 2,865,156 | Cold sensitivity in essential hypertension: the effect of beta- and combined alpha- and beta-blockade. | Eur J Clin Pharmacol | 1985 | https://conductscience.org/library/papers/2865156 | PubMed |
| 2,859,870 | Improvement in angina pectoris with alpha adrenoceptor blockade. | Br Heart J | 1985 | https://conductscience.org/library/papers/2859870 | PubMed |
| 526,408 | Labetalol, an alpha- and beta-adrenoceptor-blocking agent: its use in therapeutics. A summary of the symposium. | Br J Clin Pharmacol | 1979 | https://conductscience.org/library/papers/526408 | PubMed |
Data dates
The date of each source this release read.
- Trials
- 2026-11-12
- Gene search
- 2026-11-11
- Pipelines
- 2026-09-18
None in this release
- Grants
- Trials
- Comments and corrections
- Genes
- Drugs
- Data
Sources 11
- ChEMBL, through Open TargetsCC BY-SA 3.0
- ClinicalTrials.govNo license stated
- HGNCCC0
- iCiteCC BY 4.0
- NCBI GenePublic domain (US government)
- NIH RePORTER's grant and paper linksPublic domain
- Open TargetsCC0 1.0
- PMC's ID filePublic domain (US government)
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0
Each source's terms
- ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- ClinicalTrials.govnone stated
- HGNCCC0: https://www.genenames.org/about/license/
- iCiteCC BY 4.0
- NCBI GeneNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
- NIH RePORTER's grant and paper linksPublic domain (NIH RePORTER)
- Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- PMC's ID fileNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0. UniProt's licence file: "All databases and documents in the UniProt FTP directory may be copied and redistributed freely, without advance permission, provided that this copyright statement is reproduced with each copy." UniProt asks that users cite its latest paper: The UniProt Consortium, UniProt: the Universal Protein Knowledgebase in 2025, Nucleic Acids Research 53:D609-D617, https://doi.org/10.1093/nar/gkae1010. Read on 9 Nov 2026 at https://www.uniprot.org/help/license
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this paper from software.
The record and each of its lists are JSON, twenty rows a page. No key.
GET https://conductscience.org/api/papers/v1/43164
GET https://conductscience.org/api/papers/v1/43164/authors